CD274 and neoplasm: In view of this, Yao et al. (2022) designed a synergistic antitumor platform, BMS/RA@CC-L, using CT26 cancer-cell biomimetic nanoparticles, combining a chemotherapeutic drug (RA-V) and PD-1/PD-L1 against hypoxic tumor.